HQ: Plymouth Meeting, PA
Leadership: Jeffrey Aronin, Jeffrey Dayno, M.D.
Website: harmonybiosciences.com
Opportunity: Develop and commercialize novel treatment options for people living with rare neurological diseases. With an initial focus on sleep/wake disorders, the company’s goal is to improve the lives of patients with first-in-class, mechanism-based treatment approaches.
Vision: Develop and provide new medications to help people who are living with rare diseases.
Status: Active
> First partnered with Valor in 2017.
> Wakix®, Harmony Biosciences, LLC’s lead product, received FDA approval in August 2019 and is commercially available in the U.S. as of November 2019.
> Developed by Bioprojet and marketed in Europe since 2016, Wakix®, has the potential to provide significant improvement in the effectiveness of treatments for patients living with narcolepsy, a condition which impacts up to 200,000 Americans.
> In 2020, Harmony Biosciences, LLC was recognized nationally among the top 10 biopharmaceutical companies on the 2020 Fortune Best Workplaces in Health Care & Biopharma™ list.
